Core Insights - Haohai Biological Technology (06826) reported a mid-year performance for 2025, with revenue approximately RMB 1.293 billion, a year-on-year decrease of about 7.48% [1] - Profit attributable to ordinary equity holders was approximately RMB 211 million, down about 10.29% compared to the same period in 2024 [1] - Basic earnings per share were RMB 0.91, with an interim dividend of RMB 0.40 per share [1] Revenue Breakdown - The company focused on four core business segments: medical aesthetics, ophthalmology, orthopedics, and anti-adhesion & hemostasis, while navigating external challenges and opportunities [1] - Revenue from the ophthalmology product line decreased by approximately RMB 83.51 million, a decline of about 18.57% compared to 2024 [1] - Revenue from the medical aesthetics and wound care product line fell by approximately RMB 58.55 million, a decrease of about 9.27%, primarily due to reduced domestic demand for first and second-generation hyaluronic acid products [1] Tax Policy Impact - According to the National Taxation Administration's policy, the VAT rate for related products produced by the subsidiary Shanghai Qisheng was adjusted from 3% to 13%, leading to a decline in sales price and revenue for these products [2] - Revenue from the anti-adhesion and hemostasis product line increased by approximately RMB 4.11 million, an increase of about 59.68%, mainly due to the inclusion of the "Kangrui Gel" product in the "New and Excellent Drug and Medical Device Directory" in Shanghai [2] - The inclusion in the directory allows for expedited access to public hospitals in Shanghai and priority in medical insurance negotiations, enhancing patient payment willingness [2]
昊海生物科技公布中期业绩 普通股权益持有人应占利润约为2.11亿元 同比下降约10.29%